



(11) **EP 2 877 159 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
14.02.2018 Bulletin 2018/07

(45) Date of publication and mention
of the grant of the patent:
08.11.2017 Bulletin 2017/45

(21) Application number: **13745549.9**

(22) Date of filing: **26.07.2013**

(51) Int Cl.:
A61K 9/14 ^(2006.01) **A61K 31/473** ^(2006.01)
A61K 9/51 ^(2006.01)

(86) International application number:
PCT/US2013/052402

(87) International publication number:
WO 2014/018932 (30.01.2014 Gazette 2014/05)

(54) **EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME**
EFFLUX-INHIBITORZUSAMMENSETZUNGEN UND BEHANDLUNGSVERFAHREN DAMIT
COMPOSITIONS INHIBITRICES D'ÉCOULEMENT ET MÉTHODES DE TRAITEMENT À L'AIDE
CELLES-CI

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **27.07.2012 US 201261676689 P**

(43) Date of publication of application:
03.06.2015 Bulletin 2015/23

(73) Proprietor: **Izumi Technology, LLC.**
Lexington, MA 02420 (US)

(72) Inventors:
• **VAN TELLINGEN, Olaf**
NL-1507 TC Zaandam (NL)
• **BUNT, Antonius, Martinus Gustave**
Lexington, MA 02420 (US)

(74) Representative: **FRKelly**
27 Clyde Road
Dublin D04 F838 (IE)

(56) References cited:
US-A1- 2009 170 880

- **BREEDVELD P ET AL: "The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 7, 1 April 2005 (2005-04-01), pages 2577-2582, XP007901255, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-04-2416**
- **DE VRIES N A ET AL: "P-Glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 21, 1 November 2007 (2007-11-01), pages 6440-6449, XP002502538, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1335**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).